# MariTide Dosing Guide: Once-Monthly 140–420 mg Phase 2 Map
> Note: PeptIQ is not a medical provider. MariTide (maridebart cafraglutide) is investigational. Doses below reflect published Phase 2 designs — not a consumer protocol.
MariTide is Amgen's long-acting peptide-antibody conjugate (formerly AMG 133), built for once-monthly (or less frequent) subcutaneous dosing. That monthly cadence is the SEO differentiator versus weekly tirzepatide / retatrutide calendars.
Quick Answer: MariTide Dosage
| Setting | Public Phase 2 anchors |
|---|---|
| Fixed monthly doses | 140 mg, 280 mg, 420 mg every 4 weeks |
| Less frequent arm | 420 mg every 8 weeks (no escalation) |
| Escalation arms | Climb to 420 mg every 4 weeks over 4-week or 12-week escalation |
| Route | Subcutaneous |
| Primary readout window | Weight change at week 52 |
What Phase 2 Showed
In the NEJM Phase 2 program (NCT05669599):
Obesity without T2D (efficacy-style public summaries): up to about ~20% mean weight loss at 52 weeks vs ~2–3% placebo, without a clear plateau.
Obesity with T2D: up to about ~17% mean weight loss, with HbA1c reductions up to roughly 2.2 percentage points in Amgen communications.
Treatment-policy / intention-to-treat style means in the NEJM report were somewhat lower (roughly low-to-mid teens % in the obesity cohort across active arms) — always check which estimand a headline uses.
Why Escalation Exists
GI adverse events were common. Public summaries note they were less frequent with dose escalation and lower starting doses. That is the same titration philosophy as weekly incretins — just on a monthly clock.
MariTide vs Weekly Incretins (Dosing Mental Model)
| MariTide | Typical weekly GLP-1 / dual / triple | |
|---|---|---|
| Cadence | Monthly (± less frequent arms) | Weekly |
| Phase 2 top anchors | 140–420 mg | Multi-mg weekly ladders |
| Design | Peptide-antibody conjugate | Peptide agonists |
| Adherence pitch | Fewer injections / year | Familiar weekly habit |
Do not convert milligrams across products.
What to Track
- Injection date (monthly calendar)
- Escalation step and target maintenance dose
- 72-hour GI scores after each monthly shot
- Protein + resistance training
- Average weight, waist, labs (A1c if diabetic)
FAQ
Q: What is the MariTide dose?
A: Phase 2 studied 140, 280, and 420 mg every 4 weeks, plus 420 mg every 8 weeks and escalation schemes to 420 mg. There is no approved consumer dose.
Q: Is MariTide weekly or monthly?
A: Designed primarily as once monthly (every 4 weeks), with less-frequent arms also explored.
Q: Is MariTide the same as tirzepatide?
A: No. Different molecule, sponsor, and dosing cadence.
Bottom Line
MariTide dosing literacy starts with monthly 140 / 280 / 420 mg Phase 2 anchors, escalation for tolerability, and ~52-week weight-loss signals up to ~20% in efficacy-style summaries. Treat it as pipeline education — then track whatever your clinician actually uses.
Download PeptIQ to log monthly metabolic doses without losing the plot.
Educational content only. Not medical advice.
